Core Viewpoint - The company is committed to enhancing operational performance and actively expanding business orders to reward investor support [1] Group 1 - The management and all employees of the company will continue to strive for improved business performance [1] - The company adheres strictly to relevant laws and regulations regarding order-related matters [1] - The company will fulfill its information disclosure obligations promptly if it meets the relevant disclosure standards [1]

（编辑 任世碧） 证券日报网讯 12月25日，睿智医药在互动平台回答投资者提问时表示，目前公司生产经营活动一切正 常，各项业务有序推进。公司将持续聚焦主业，扎实经营，努力提升核心竞争力和盈利能力，以回报广 大投资者的信任。在市值管理方面，公司董事会及管理层始终高度重视市值表现与投资者关系维护。公 司坚持通过法定信息披露渠道及时、准确、完整地披露公司经营与治理情况，并通过业绩说明会、投资 者热线、互动易平台等多种方式与投资者保持积极、透明的沟通交流，致力于让市场更充分、更准确地 认识公司的内在价值。未来，公司将继续规范运作，提升经营质量，积极传递公司价值，用高质量发展 回馈市场信任与投资者支持。 ...

Group 1: Financing Trends - The technology and manufacturing sectors, along with healthcare, continue to dominate the financing market with a high density of cases and significant funding amounts [1] - In the past week, over 20 financing cases were reported in the technology and manufacturing sectors, including multiple transactions exceeding 500 million RMB [1] - The healthcare sector is also showing steady growth, with large transactions and innovative sub-sectors receiving attention [1] Group 2: Regional Financing Distribution - The majority of financing activities were concentrated in Jiangsu Province, Beijing, and Guangdong Province, with 7, 6, and 5 cases respectively [3] Group 3: Active Investment Institutions - Yizhuang Guotou and Guoke Investment were notably active, each disclosing 2 investments primarily in the technology and manufacturing, as well as healthcare sectors [5] Group 4: Notable Financing Cases in Healthcare - Beijing Bohui Biotechnology completed nearly 100 million RMB in A+ round financing, led by Yizhuang Guotou, to accelerate clinical progress and expand its pipeline [7] - Suzhou Jishi Medical Technology completed A round financing, focusing on eye disease treatment and prevention solutions [8] - Suzhou Baifu Laser Technology completed over 100 million RMB in C round financing to enhance product development and market expansion [9] - Kangyuan Bochuang completed 250 million RMB in B round financing to advance research in tumor immunity and next-generation kinase inhibitors [10] Group 5: Notable Financing Cases in Technology and Manufacturing - Chengdu Xinglian Xintong completed over 100 million RMB in B round financing to strengthen its position in the satellite communication sector [17] - Suzhou Xinshi Nuo Semiconductor Equipment completed over 500 million RMB in A+ round financing to enhance its capabilities in semiconductor automation [18] - Shanghai Fangqing Technology completed over 500 million RMB in Pre-A round financing to advance its distributed AI computing architecture [20] Group 6: Additional Notable Financing Cases - Shenzhen Haodian Technology completed over 100 million RMB in B round financing, focusing on lithium battery adhesive development [21] - Suzhou Junji Gene Technology completed nearly 100 million RMB in A round financing to enhance its automated gene technology applications [22] - Jiangxi Panmeng Semiconductor completed over 100 million RMB in A+ round financing for capacity expansion and technology development [39]

（编辑 任世碧） 证券日报网讯 12月22日，睿智医药在互动平台回答投资者提问时表示，胡瑞连先生直接持有公司股份 55482062股，并通过其一致行动人MEGASTARCENTRELIMITED、江门睿联医药投资有限公司分别持 有公司股份22711333股、26641074股，合计持有公司股份104834469股，占公司总股本497963992股的 21.05%。公司股东持股信息，请以公司在巨潮资讯网等指定信息披露媒体发布的信息为准。 ...

证券代码：300149 证券简称：睿智医药 公告编号：2025-82 睿智医药科技股份有限公司 关于关联方对全资子公司增资进展暨完成工商登记的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 睿智医药科技股份有限公司（以下简称"公司"）于 2025 年 10 月 29 日召开的 第六届董事会第十三次会议审议通过了《关于关联方对全资子公司增资及对外投 资设立合资公司暨关联交易的议案》，为满足公司全资子公司广东享百年健康科 技有限公司（以下简称"享百年健康科技"）经营发展需求，增强其资本实力， 同意增资扩股引入公司关联方江门市安欣投资有限公司（以下简称"安欣投资"） 以货币方式向享百年健康科技增资人民币 4,803,921.57 元。具体内容详见公司于 2025 年 10 月 30 日在巨潮资讯网（www.cninfo.com.cn）上披露的《关于关联方对 全资子公司增资及对外投资设立合资公司暨关联交易的公告》（公告编号： 2025-71）。 一、增资扩股的进展情况 近日，享百年健康科技已完成上述事项的工商变更手续，并取得了广州市越 秀区市场监督管理局换发的《 ...

证券代码：300149 证券简称：睿智医药 公告编号：2025-81 睿智医药科技股份有限公司 关于担保进展的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 根据《深圳证券交易所创业板股票上市规则》、《深圳证券交易所上市公司 自律监管指引第 2 号——创业板上市公司规范运作》等相关文件的规定，上述担 保额度在公司董事会、股东会批准的额度范围之内，无需再次提交公司董事会或 股东会审议。 三、被担保人基本情况 一、担保情况概述 睿智医药科技股份有限公司（以下简称"公司"）分别于 2025 年 4 月 27 日、 2025 年5 月 30日召开第六届董事会第六次会议、第六届监事会第六次会议和 2024 年年度股东会，审议通过了《关于向银行等金融机构申请综合授信额度并提供担 保的议案》，同意 2025 年度公司为子公司（含子公司之间）提供担保额度合计为 不超过人民币 18,000 万元。具体内容详见公司于 2025 年 4 月 29 日在巨潮资讯网 （www.cninfo.com.cn）上披露的《关于向银行等金融机构申请综合授信额度并提 供担保的公告》（公告编号 ...

Group 1 - The core viewpoint of the article is that Ruizhi Pharmaceutical has clarified its main business focus on equity investment through a response to investor inquiries on an interactive platform [2] Group 2 - The company emphasizes the importance of monitoring its related announcements for further information regarding its business operations [2]

Core Insights - The core principle of drug development should be disease treatment, emphasizing the importance of understanding diseases and their mechanisms to improve drug research efficiency and success rates [3] Group 1: Company Overview - Zheyuan Technology, an AI4S (AI For Science) company, recently completed a financing round of over 100 million yuan, led by Guoke Investment [2] - The company positions itself as an "AI4S + disease" firm, focusing on a "computational medicine" platform to empower drug innovation, particularly in discovering new mechanisms and targets, as well as enhancing clinical trial processes [3] Group 2: Technological Innovations - Zheyuan Technology has developed a "virtual clinical trial" capability, which involves creating digital twins of patients to simulate drug responses based on individual omics data [4] - The platform allows for the evaluation of drug effects across thousands of potential indications during the drug pipeline validation phase, demonstrating AI's predictive capabilities in real projects [4] Group 3: Clinical Applications - In collaboration with Beijing Cancer Hospital, Zheyuan Technology conducted a virtual clinical parallel trial, predicting drug responses for eight enrolled patients, with AI predictions aligning perfectly with actual clinical trial results [5] - This approach enables the identification of suitable indications for drugs before formal human trials, potentially accelerating the clinical trial process [5] Group 4: Industry Challenges and Methodology - The market remains skeptical about the technological capabilities and commercial value of AI in drug development, particularly in complex areas like new target discovery and virtual clinical trials [6] - Zheyuan Technology's CEO outlines a five-level methodology for assessing innovative technology capabilities, ranging from identifying opportunities to producing verifiable results [6] Group 5: Business Model and Industry Impact - Zheyuan Technology aims to create an innovative drug "IP factory," leveraging a mature supply chain in the pharmaceutical industry to efficiently convert resources into drug assets [7] - The company seeks to transform drug development from an art into a predictable and replicable engineering process, addressing the industry's challenges of high costs and low success rates [7]

证券日报网讯 12月16日，睿智医药在互动平台回答投资者提问时表示，公司严格按照相关法律法规履 行信息披露义务，如签订达到披露标准的重大合同，公司将严格按照监管要求及时进行公告。股价受宏 观经济、行业政策、市场情绪等多重复杂因素共同影响。公司管理层始终专注于主营业务，致力于通过 提升经营管理效率和核心竞争力，以扎实的业绩和长期的成长回报广大投资者的信任。 （文章来源：证券日报） ...

证券日报网讯12月16日，睿智医药（300149）在互动平台回答投资者提问时表示，公司严格按照相关法 律法规履行信息披露义务，不存在应披露而未披露的重大信息。目前公司经营稳健，请关注公司在法定 信息披露媒体上发布的定期报告与相关公告。 ...